An interventional study of TIER-HF-PC and Usual Care in Heart Failure, sponsored by National Cancer Centre, Singapore. Recruiting at 4 sites in Singapore. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by National Cancer Centre, Singapore · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Heart Failure with a site in Singapore — 6 open to participants now, 14 under way, 2 of them phase 3. Heart Failure · Singapore.
Among the 62 studies in Heart Failure with a site in Singapore, this one is the 27th largest by planned enrollment of the 46 interventional ones that give a count, is one of 5 that started in 2024, is one of 17 with no phase, reaches primary completion later than 5 of the 13 other live ones, and was the 56th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →6 of the 62 studies in Heart Failure with a site in Singapore are open now. Recruiting first, the newest first:
Abbott Medical Devices · Sites in Singapore, Brazil, France and 6 more countries
Ages 18+
National Heart Centre Singapore · Sites in Singapore
Ages 21–99 · Healthy volunteers
Merck Sharp & Dohme LLC · Sites in Singapore, United States, Belgium and 27 more countries
Ages 29 days–17 yrs
National University Heart Centre, Singapore · Sites in Singapore
Ages 18+
National University Hospital, Singapore · Sites in Singapore
Ages 40–99
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 21 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 17 · Phase 4 4
First in 2006; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 310 across the 46 interventional studies, 678 across the 16 observational. Of the 45 that completed or were terminated, 27 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 62 have an industry lead sponsor. The 10 most frequent:
National Cancer Centre, Singapore is the lead sponsor of 117 studies on the registry; 29 are open to participants now.
National Cancer Centre, Singapore has 2 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
3 of the studies in Heart Failure with a site in Singapore that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT06090734Duke-NUS Graduate Medical SchoolDevelopment and Evaluation of 'My Voice': A Randomized Controlled Trial | 2027-03 |
| NCT07217392Abbott Medical DevicesLeft Bundle Branch Area Pacing (LBBAP) PMCF Study | 2027-04-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 62 studies in Heart Failure with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
There is evidence for the effectiveness and feasibility of the individual components of TIER-HF-PC, however there is a need to test how these individual components interact to allow the researchers to deliver TIER-HF-PC as a model of care in its totality. In the short term, this study will assess if TIER-HF-PC is beneficial for patients and caregivers.
Timely Interventions to Enable and Reach patients with Heart Failure, and their caregivers with Palliative Care, or TIER-HF-PC, is a novel model of palliative care, designed to address gaps of palliative care delivery for patients with advanced heart failure, and their caregivers.
TIER-HF-PC is a service, led by a health coach, with support by a palliative care physician. This health coach will actively screen and monitor patients for problems, and then match the type and intensity of palliative care treatments to the severity of problems reported. The health coach will also facilitate processes for patients to initiate contact with health care providers should problems arise. This decreases the overall burden on palliative care services, enabling a scalable and more cost-effective model of care for a larger number of patients. The service will also utilize a proactive approach to care, increasing self-care skills and understanding of disease and treatment options. Earlier palliative care support will enable problems to be managed actively before they escalate into crises.
Overall aim: To test the effectiveness and implementation of the interacting components of TIER-HF-PC.
Specific aim 1a: To evaluate the impact of TIER-HF-PC on patients. The primary outcome is patient quality-of-life at 24 weeks, measured on the Kansas City Cardiomyopathy Questionnaire. Secondary outcomes include patient anxiety, depression, coping, spirituality, healthcare utilization, survival, and cost-effectiveness of TIER-HF-PC.
Specific aim 1b: To evaluate the impact of TIER-HF-PC on caregivers. Outcomes evaluated include caregiver quality-of-life.
- Hypothesis 1: The researchers hypothesize that TIER-HF-PC will be superior to usual care, in improving patient and caregiver quality-of-life.
Specific aim 2: To evaluate the implementation outcomes of TIER-HF-PC.
- Hypothesis 2: The researchers hypothesize that participants will be satisfied with the TIER-HF-PC service, though modifications might be needed for fine-tuning of the appropriateness and timeliness of care provision in TIER-HF-PC. They will evaluate these implementation outcomes through a validated service evaluation survey and semi-structured interviews. Fidelity to study protocols will be assessed through audits of case notes and study processes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients:
Caregivers must meet all the following inclusion criteria to be eligible for the study :
Exclusion Criteria:
Patients:
Caregivers who meet any of the exclusion criteria at baseline will be ineligible for the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The patient continues to receive clinical care from the cardiologist, as well as palliative care treatments that are based upon his/her reported distress and concerns.
Other: TIER-HF-PC
Patient is referred by cardiologist to palliative care.
Other: Usual Care
The patient will be assigned to one of the three levels of care which is determined by the results given by Distress Thermometer (DT) and the Integrated Palliative Care Outcome Scale (IPOS).
Patient continues on clinical care by his/her cardiologist. If the cardiologist picks up their symptoms or other concerns, he/or can be referred to a specialist palliative care physician by the cardiologist.
Patient quality of life (QOL) per the KCCQ-12 Questionnaire
The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) will be used: It is a 12-item QOL scale, composed of physical function, symptoms, QOL, social interference and summary score will be used. The KCCQ-12 has similar validity to the 23-item version and is shorter with less respondent burden. The KCCQ-12 can be self-reported by patients or read to patients over the phone by a research coordinator. The total summary score can range from 0 to 100, with higher scores representing better health status. A clinically meaningful change is defined as a change of at least 5 points on the KCCQ. The KCCQ-12 will be measured for all participants (TIER-HF-PC and usual care), and tracked every 8 weeks from baseline, till the point of patient death, or till week 48, whichever is earlier. The frequency of our proposed KCCQ tracking is referenced from trials which used KCCQ to track longitudinal changes in QOL.
Time frame: Every 8 weeks from baseline, till the point of patient death, or till week 48, whichever is earlier.
Patient quality of life (QOL) per the EUROQOL EQ-5D-5L Questionnaire
The non cardiac specific health-related quality of life (EUROQOL EQ-5D-5L) questionnaire will also be used: This is a global assessment of the patient's quality-of-life in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, that can also be administered over the phone. The results from the 5 dimensions can be combined into a 5-digit number that describes the patient's health state utility. The EQ-5D-5L has been validated in the Singapore cardiac population.
Time frame: Baseline, 8 weeks, 16 weeks, and 24 weeks.
Caregiver Quality of Life (QOL)
The Singapore Caregiver Quality of Life Scale-15 (SCQOLS-15) will be used: This is a 15-item scale with 5 domains measuring QOL of life caregivers in domains: physical well-being, mental well-being, experience and meaning, impact on daily life, and financial well-being will be used. This will be measured for all caregiver participants (TIER-HF-PC and usual care), and tracked every 8 weeks from baseline, till the point of patient death, or till week 48, whichever is earlier. A difference of between 3-5 points in QOL scores could serve as a benchmark to evaluate if the difference between intervention and usual-care group is meaningful.
Time frame: Every 8 weeks from baseline, till the point of patient death, or till week 48, whichever is earlier.
Acceptability of TIER-HF-PC from patient and caregiver participants - through completion of the client satisfaction questionnaire (CSQ-4)
The client satisfaction questionnaire (CSQ-4) will be used. The total score of the CSQ per participant will be computed. Analysis will be conducted on the patient and caregiver scores separately. The percentage of participants in TIER-HF-PC who have at least a CSQ score of 12 and above will also be calculated.
Time frame: At Week 25.
Acceptability of TIER-HF-PC from patient and caregiver participants - through semi-structured interviews
Regarding the analysis of semi-structured interviews, a qualitative coding team who is experienced in qualitative analysis will be formed. Interviews will be open coded line by line. Code categories will be developed and iteratively adjusted through discussions. The code categories will be subsequently mapped back to the main domains of the RE-AIM and PRISM framework to identify key multi-level contextual factors influencing the TIER-HF-PC outcomes as well as to assess the adoption, implementation, and impact of TIER-HF-PC. Hence, the analysis will involve both inductive and deductive approaches.
Time frame: From Week 25 onwards, up to Week 48.
Patient anxiety and depression
The Hospital Anxiety and Depression Scale (HADS) will be used. This is a 14-item scale with a score range of 0 to 42. It is composed of two subscales- anxiety and depression- with a cut-off point of 11 for each subscale, that determines anxiety and depression of clinical significance.
Time frame: Baseline, 8 weeks, 16 weeks, and 24 weeks.
Patient and Caregiver Spirituality
The Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being 12 Item Scale (Facit-SP-12)/Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being Non-Illness (FACIT-Sp Non-Illness) will be used. This is a 12-item survey that measures the spiritual well-being of patients and caregivers. The total of Facit-SP-12/ FACIT-Sp Non-Illness ranges from 0 to 48 with higher scores representing increased spirituality.
Time frame: Baseline, 8 weeks, 16 weeks, and 24 weeks.
Patient and Caregiver Coping
Brief Coping with Problems Experienced (Brief-COPE) scale will be used. It is a 28-item scale measuring the ways people cope with stressful events. It has been used in the heart failure population, where the coping style was shown to correlate with the level of physical functioning.
Time frame: Baseline, 8 weeks, 16 weeks, and 24 weeks.
Assessment of impact of TIER-HF-PC on healthcare utilization
The differences in community hospice usage, number and length of hospital admissions, number of emergency visits, number, and length of intensive care visits between TIER-HF-PC participants and those in usual care will be assessed using generalized linear models, with binomial model for community hospice usage and Poisson model with robust standard effort for other healthcare utilization outcomes.
Time frame: Week 1 to Week 24.
Healthcare cost analysis
The total cost of inpatient bills and outpatient bills including emergency visit bills for TIER-HF-PC participants and usual care participants from week 1 to week 24 will be summed up and the cost differences between both groups will be quantified by generalized linear model with Gamma model and robust standard error. The net cost of the TIER-HF-PC model will be calculated based upon the cost of care provision in TIER-HF-PC minus the cost savings from reduction of health care utilization. We will also calculate incremental cost-effectiveness ratios (ICERs) to measure the average net cost per quality-adjusted-life-year (QALY) gained for TIER-HF-PC versus usual care participants. The QALY will be calculated by the product of quality-of-life (EQ-5d-5L) and survival.
Time frame: Up to 24 weeks.
Survival analysis
The differences in survival between TIER-HF-PC and usual care will be analyzed using a Cox model regression, censoring at week 48 or death, whichever occurs earlier.
Time frame: Up to 48 weeks.
Plan to share: Undecided
Started Aug 2024 (actual). Primary completion is estimated for Oct 2026, 26 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 26 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Cancer Centre, Singapore →